375 related articles for article (PubMed ID: 24007691)
21. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
22. Expression of FOXL2 in human normal pituitaries and pituitary adenomas.
Egashira N; Takekoshi S; Takei M; Teramoto A; Osamura RY
Mod Pathol; 2011 Jun; 24(6):765-73. PubMed ID: 21478824
[TBL] [Abstract][Full Text] [Related]
23. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
24. Follicle stimulating hormone-beta subunit gene is expressed in parallel with a transcription factor Ad4BP/SF-1 in human pituitary adenomas.
Ikuyama S; Ohe K; Sakai Y; Nakagaki H; Fukushima T; Kato Y; Morohashi K; Takayanagi R; Nawata H
Clin Endocrinol (Oxf); 1996 Aug; 45(2):187-93. PubMed ID: 8881451
[TBL] [Abstract][Full Text] [Related]
25. [The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases].
Asano K; Kubo O; Tajika Y; Huang MC; Takakura K
No To Shinkei; 1996 Jun; 48(6):543-9. PubMed ID: 8703557
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of human natural killer cell like immunoreactivity in human pituitary adenomas, using monoclonal antibody NK-1.
Sanno N; Itoh J; Teramoto A; Itoh Y; Hori S; Osamura RY
J Neurooncol; 1997 Oct; 35(1):29-38. PubMed ID: 9266438
[TBL] [Abstract][Full Text] [Related]
27. [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].
Fedorova NS; Abrosimov AY; Dzeranova LK; Pigarova EA; Dedov II
Arkh Patol; 2018; 80(3):34-39. PubMed ID: 29927438
[TBL] [Abstract][Full Text] [Related]
28. Double separate versus contiguous pituitary adenomas: MRI features and endocrinological follow up.
Roberts S; Borges MT; Lillehei KO; Kleinschmidt-DeMasters BK
Pituitary; 2016 Oct; 19(5):472-81. PubMed ID: 27209585
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor.
Sun B; Liu X; Yang Y; Dai C; Li Y; Jiao Y; Wei Z; Yao Y; Feng M; Bao X; Deng K; Wang N; Wang R
J Mol Neurosci; 2016 Jan; 58(1):137-44. PubMed ID: 26676407
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas.
Sanno N; Sugawara A; Teramoto A; Abe Y; Yen PM; Chin WW; Osamura RY
Neuroendocrinology; 1997 Apr; 65(4):299-306. PubMed ID: 9143002
[TBL] [Abstract][Full Text] [Related]
31. Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67.
Sen A; Das C; Mukhopadhyay M; Mukhopadhyay S; Deb S; Mukhopadhyay B
J Postgrad Med; 2017; 63(2):96-99. PubMed ID: 27779153
[TBL] [Abstract][Full Text] [Related]
32. Identification and consequences of galectin-3 expression in pituitary tumors.
Righi A; Jin L; Zhang S; Stilling G; Scheithauer BW; Kovacs K; Lloyd RV
Mol Cell Endocrinol; 2010 Sep; 326(1-2):8-14. PubMed ID: 20451577
[TBL] [Abstract][Full Text] [Related]
33. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
34. Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.
DeStephano DB; Lloyd RV; Pike AM; Wilson BS
Am J Pathol; 1984 Sep; 116(3):464-72. PubMed ID: 6089568
[TBL] [Abstract][Full Text] [Related]
35. Detection of growth hormone, prolactin and human beta-chorionic gonadotropin mRNA in growth hormone-secreting pituitary adenomas and in prolactin-secreting pituitary adenomas by in situ hybridization using a non-isotopic detection method.
Tallen G; Fehr S; Saeger W; Uhlig H; Lüdecke DK
Acta Endocrinol (Copenh); 1993 May; 128(5):411-7. PubMed ID: 8317187
[TBL] [Abstract][Full Text] [Related]
36. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
37. GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.
Münscher A; Schmid M; Saeger W; Schreiber S; Lüdecke DK
Endocr Pathol; 2001; 12(2):171-80. PubMed ID: 11579683
[TBL] [Abstract][Full Text] [Related]
38. GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.
Sanno N; Teramoto A; Matsuno A; Takekoshi S; Osamura RY
J Clin Endocrinol Metab; 1995 Aug; 80(8):2518-22. PubMed ID: 7543115
[TBL] [Abstract][Full Text] [Related]
39. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture.
Yamaji T; Ishibashi M; Teramoto A; Fukushima T
Acta Endocrinol (Copenh); 1985 Apr; 108(4):456-63. PubMed ID: 2859725
[TBL] [Abstract][Full Text] [Related]
40. Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas.
Wu Y; Liu C; Yu S; Gao H; Li Z; Li C; Zhang Y
Oncol Rep; 2016 May; 35(5):2991-9. PubMed ID: 26935389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
